Scribe Therapeutics Inc.

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Scribe Therapeutics posted Q2 2026 collaboration revenue of $1.9 million, down from $4.9 million a year earlier, and narrowed its net loss to $6.5 million, or $2.62 per share, from $9.9 million, or $4.08, in the prior-year quarter. The company initiated the first-in-human Phase 1 trial of lead PCSK9-silencing asset STX-1150 in Australia, with initial single-ascending-dose data expected in the first half of 2027, and won roughly $25.7 million in combined CIRM grants to advance STX-1200 (Lp(a) lowering) and STX-1400 (triglyceride lowering) toward clinical entry as early as 2027. Scribe's July 2026 upsized IPO priced at $15.00 per share, plus a concurrent private placement to Sanofi, generated about $155.5 million gross ($140.6 million net), which together with $43.0 million in cash on hand funds operations into the first half of 2029.

•1mo ago

Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement

Scribe Therapeutics has closed its upsized initial public offering, selling 9,867,000 shares at $15.00 per share to raise aggregate gross proceeds of approximately $155.51 million. The offering included the full exercise of the underwriters' option and a concurrent private placement of 500,000 shares to Sanofi at the IPO price. Shares of Scribe Therapeutics began trading on the Nasdaq Global Market on July 24, 2026 under the ticker symbol SCTX.

•2mo ago